A Study to Assess Growth in Children With Idiopathic Short Stature
Purpose
Study 111-903 will generate baseline growth data in children with ISS by collecting growth measurements and other variables of interest.
Condition
- Idiopathic Short Stature
Eligibility
- Eligible Ages
- Between 2 Years and 16 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Participants must be > 2 years old, and ≤ 14 years old (female) or ≤ 16 years old (males) at the time of signing the informed consent. 2. A height assessment corresponding to a height Z-score of ≤ -2.25 SDs in reference to the general population of the same age and sex, as calculated using the Centers for Disease Control and Prevention (CDC) growth chart (https://www.cdc.gov/growthcharts/zscore.htm). 3. Participants who have either never received hGH, or who are currently receiving hGH treatment. 4. Historic stimulation test result with serum or plasma GH level greater than 10 μg/L. 5. Parent(s) or guardian(s) are willing and able to provide written, signed informed consent.
Exclusion Criteria
- Diagnosis of systemic disease or condition that may cause short stature, eg renal, neoplastic, pulmonary, cardiac, gastrointestinal, immunologic and metabolic disease. Children with such diagnoses can be considered for inclusion if their condition is well controlled, at the discretion of the Medical Monitor. 2. Known presence of one or more pituitary hormone deficiencies 3. Bone age advanced over chronological age by more than 3 years. 4. For hGH naïve participants, historic stimulation test result with serum or plasma GH level greater than 10 μg/L or serum IGF-1 in the normal range for age (between -1.00 SDs and +2.00 SDs). 5. For participants currently on hGH treatment, historic results before GH treatment of stimulation test with serum or plasma GH level greater than 10 μg/L or serum IGF-1 test between -1.00 SDs and +2.00 SDs. 6. Have received an investigational product (IP) or investigational medical device for any purpose within 6 months before the Screening visit. .
Study Design
- Phase
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Other
Recruiting Locations
Phoenix, Arizona 85016
Los Angeles, California 90027
Los Angeles, California 90502
Orange, California 92868
Sacramento, California 95821
San Diego, California 92123
San Francisco, California 94143
Hartford, Connecticut 06106-3322
New Haven, Connecticut 06511
Washington D.C., District of Columbia 20010
Jacksonville, Florida 32207
Miami, Florida 33155
Pensacola, Florida 32514
Columbus, Georgia 31904
Boise, Idaho 83712
Idaho Falls, Idaho 83404-7596
Idaho Falls, Idaho 83404
Louisville, Kentucky 40202
New Orleans, Louisiana 70121
Ann Arbor, Michigan 48109-4000
Minneapolis, Minnesota 55454
Lebanon, New Hampshire 03756
Princeton, New Jersey 08540
Buffalo, New York 14203
Garden City, New York 11530
New York, New York 10016
New York, New York 10029
The Bronx, New York 10467
Raleigh, North Carolina 27615
Cincinnati, Ohio 45229
Columbus, Ohio 43205
Columbia, South Carolina 29203
Nashville, Tennessee 37232-2578
Dallas, Texas 75390
Fort Worth, Texas 76104
Houston, Texas 77030
Seattle, Washington 98105
Charleston, West Virginia 25304
Charleston, West Virginia 25304
Milwaukee, Wisconsin 53226
More Details
- NCT ID
- NCT06309979
- Status
- Recruiting
- Sponsor
- BioMarin Pharmaceutical